Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Gets Deficiency Notice from Nasdaq

NEW YORK (GenomeWeb News) – Compugen has received a letter from Nasdaq stating that the firm is currently not in compliance with listing regulations.

The Tel Aviv-based company said that it received the letter on May 28. The firm is not in compliance with regulations that state that it must have at least $10 million in stockholders' equity. As of March 31, Compugen had stockholders' equity of around $8.9 million.

Compugen, which currently trades on the Nasdaq Global Market Marketplace, said that it can either submit a detailed plan of compliance by June 15, or apply to transfer to the Nasdaq Capital Market.

The firm said that it believes that, as of today, it is in compliance with the listing requirements for the Nasdaq Capital Market.

In early Tuesday trade, Compugen's shares were up 4 percent at $1.30.

The Scan

Genes Linked to White-Tailed Jackrabbits' Winter Coat Color Change

Climate change, the researchers noted in Science, may lead to camouflage mismatch and increase predation of white-tailed jackrabbits.

Adenine Base Editor Targets SCID Mutation in New Study

Researchers from the University of California, Los Angeles, report in Cell that adenine base editing was able to produce functional T lymphocytes in a model of severe combined immune deficiency.

Researchers Find Gene Affecting Alkaline Sensitivity in Plants

Researchers from the Chinese Academy of Science have found a locus affecting alkaline-salinity sensitivity, which could aid in efforts to improve crop productivity, as they report in Science.

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.